ABSTRACT
BACKGROUND: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD. METHODS AND FINDINGS: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi procedure. The aim was to reach a consensus regarding clinical trial design, best treatment comparator, clinical outcomes, measurement of those clinical outcomes and inclusion and exclusion criteria. Consensus results of this initiative included: the selection of the adaptative clinical trial as the ideal study design and agalsidase beta as ideal comparator treatment due to its longstanding use in FD. Renal and cardiac outcomes, such as glomerular filtration rate, proteinuria and left ventricular mass index, were prioritised, whereas neurological outcomes including cerebrovascular and white matter lesions were dismissed as a primary or secondary outcome measure. Besides, there was a consensus regarding the importance of patient-related outcomes such as general quality of life, pain, and gastrointestinal symptoms. Also, unity about lysoGb3 and Gb3 tissue deposits as useful surrogate markers of the disease was obtained. The group recognised that cardiac T1 mapping still has potential but requires further development before its widespread introduction in clinical trials. Finally, patients with end-stage renal disease or renal transplant should be excluded unless a particular group for them is created inside the clinical trial. CONCLUSION: This consensus will help to shape the future of clinical trials in FD. We note that the FDA has, coincidentally, recently published draft guidelines on clinical trials in FD and welcome this contribution.
Subject(s)
Clinical Trials as Topic , Enzyme Replacement Therapy , Fabry Disease/drug therapy , Kidney/metabolism , Adult , Consensus , Delphi Technique , Fabry Disease/genetics , Fabry Disease/metabolism , Fabry Disease/pathology , Female , Globosides/therapeutic use , Glycolipids/therapeutic use , Humans , Isoenzymes/genetics , Kidney/drug effects , Kidney/pathology , Male , Middle Aged , Quality of Life , Sphingolipids/therapeutic use , Treatment Outcome , Trihexosylceramides/therapeutic use , alpha-Galactosidase/geneticsABSTRACT
Oculodentodigital dysplasia is an autosomal dominant disorder due to GJA1 variants characterized by dysmorphic features. Neurologic symptoms have been described in some patients but without a clear neuroimaging pattern. To understand the pathophysiology underlying neurologic deficits in oculodentodigital dysplasia, we studied 8 consecutive patients presenting with hereditary spastic paraplegia due to GJA1 variants. Clinical disease severity was highly variable. Cerebral MR imaging revealed variable white matter abnormalities, consistent with a hypomyelination pattern, and bilateral hypointense signal of the basal ganglia on T2-weighted images and/or magnetic susceptibility sequences, as seen in neurodegeneration with brain iron accumulation diseases. Patients with the more prominent basal ganglia abnormalities were the most disabled ones. This study suggests that GJA1-related hereditary spastic paraplegia is a complex neurodegenerative disease affecting both the myelin and the basal ganglia. GJA1 variants should be considered in patients with hereditary spastic paraplegia presenting with brain hypomyelination, especially if associated with neurodegeneration and a brain iron accumulation pattern.
Subject(s)
Brain/pathology , Connexin 43/genetics , Craniofacial Abnormalities/genetics , Craniofacial Abnormalities/pathology , Eye Abnormalities/genetics , Eye Abnormalities/pathology , Foot Deformities, Congenital/genetics , Foot Deformities, Congenital/pathology , Spastic Paraplegia, Hereditary/genetics , Spastic Paraplegia, Hereditary/pathology , Syndactyly/genetics , Syndactyly/pathology , Tooth Abnormalities/genetics , Tooth Abnormalities/pathology , Adolescent , Adult , Craniofacial Abnormalities/complications , Eye Abnormalities/complications , Female , Foot Deformities, Congenital/complications , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neuroimaging , Syndactyly/complications , Tooth Abnormalities/complicationsABSTRACT
OBJECTIVE: To characterize Alexander disease (AxD) phenotypes and determine correlations with age at onset (AAO) and genetic mutation. AxD is an astrogliopathy usually characterized on MRI by leukodystrophy and caused by glial fibrillary acidic protein (GFAP) mutations. METHODS: We present 30 new cases of AxD and reviewed 185 previously reported cases. We conducted Wilcoxon rank sum tests to identify variables scaling with AAO, survival analysis to identify predictors of mortality, and χ(2) tests to assess the effects of common GFAP mutations. Finally, we performed latent class analysis (LCA) to statistically define AxD subtypes. RESULTS: LCA identified 2 classes of AxD. Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features. Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features. Survival analysis predicted a nearly 2-fold increase in mortality among patients with type I AxD relative to those with type II. R79 and R239 GFAP mutations were most common (16.6% and 20.3% of all cases, respectively). These common mutations predicted distinct clinical outcomes, with R239 predicting the most aggressive course. CONCLUSIONS: AAO and the GFAP mutation site are important clinical predictors in AxD, with clear correlations to defined patterns of phenotypic expression. We propose revised AxD subtypes, type I and type II, based on analysis of statistically defined patient groups.
Subject(s)
Alexander Disease/classification , Alexander Disease/genetics , Glial Fibrillary Acidic Protein/genetics , Mutation/genetics , Adolescent , Adult , Age Factors , Age of Onset , Alexander Disease/mortality , Bayes Theorem , DNA Mutational Analysis , Exons/genetics , Female , Humans , Logistic Models , Male , Retrospective Studies , Survival Analysis , Young AdultABSTRACT
OBJECTIVE: To investigate body fluids of patients with undiagnosed leukodystrophies using in vitro (1)H-NMR spectroscopy (H-NMRS). METHODS: We conducted a cross-sectional study using high-resolution in vitro H-NMRS on CSF and urine samples. RESULTS: We found a significant increase of free sialic acid in CSF or urine in 6 of 41 patients presenting with hypomyelination of unknown etiology. Molecular genetic testing revealed pathogenic mutations in the SLC17A5 gene in all 6 patients. H-NMRS revealed an increase of N-acetylaspartylglutamate in the CSF of all patients with SLC17A5 mutation (range 13-114 micromol/L, reference <12 micromol/L). CONCLUSION: In patients with undiagnosed leukodystrophies, increased free sialic acid in CSF or urine is a marker for free sialic acid storage disorder and facilitates the identification of the underlying genetic defect. Because increase of N-acetylaspartylglutamate in CSF has been observed in other hypomyelinating disorders, it can be viewed as a marker of a subgroup of hypomyelinating disorders.
Subject(s)
Demyelinating Diseases/cerebrospinal fluid , Dipeptides/cerebrospinal fluid , Organic Anion Transporters/genetics , Sialic Acid Storage Disease/cerebrospinal fluid , Sialic Acid Storage Disease/diagnosis , Symporters/genetics , Child , Child, Preschool , Cross-Sectional Studies , Demyelinating Diseases/etiology , Demyelinating Diseases/urine , Female , Genetic Testing , Genotype , Humans , Infant , Magnetic Resonance Imaging , Magnetic Resonance Spectroscopy , Male , Mutation , N-Acetylneuraminic Acid/cerebrospinal fluid , N-Acetylneuraminic Acid/urine , Sialic Acid Storage Disease/complications , Sialic Acid Storage Disease/genetics , Sialic Acid Storage Disease/urine , Young AdultABSTRACT
BACKGROUND: We analysed 5-year treatment with agalsidase alfa enzyme replacement therapy in patients with Fabry's disease who were enrolled in the Fabry Outcome Survey observational database (FOS). METHODS: Baseline and 5-year data were available for up to 181 adults (126 men) in FOS. Serial data for cardiac mass and function, renal function, pain, and quality of life were assessed. Safety and sensitivity analyses were done in patients with baseline and at least one relevant follow-up measurement during the 5 years (n=555 and n=475, respectively). FINDINGS: In patients with baseline cardiac hypertrophy, treatment resulted in a sustained reduction in left ventricular mass (LVM) index after 5 years (from 71.4 [SD 22.5] g/m(2.7) to 64.1 [18.7] g/m(2.7), p=0.0111) and a significant increase in midwall fractional shortening (MFS) from 14.3% (2.3) to 16.0% (3.8) after 3 years (p=0.02). In patients without baseline hypertrophy, LVM index and MFS remained stable. Mean yearly fall in estimated glomerular filtration rate versus baseline after 5 years of enzyme replacement therapy was -3.17 mL/min per 1.73 m(2) for men and -0.89 mL/min per 1.73 m(2) for women. Average pain, measured by Brief Pain Inventory score, improved significantly, from 3.7 (2.3) at baseline to 2.5 (2.4) after 5 years (p=0.0023). Quality of life, measured by deviation scores from normal EuroQol values, improved significantly, from -0.24 (0.3) at baseline to -0.17 (0.3) after 5 years (p=0.0483). Findings were confirmed by sensitivity analysis. No unexpected safety concerns were identified. INTERPRETATION: By comparison with historical natural history data for patients with Fabry's disease who were not treated with enzyme replacement therapy, long-term treatment with agalsidase alfa leads to substantial and sustained clinical benefits. FUNDING: Shire Human Genetic Therapies AB.
Subject(s)
Fabry Disease/drug therapy , alpha-Galactosidase/therapeutic use , Adult , Fabry Disease/physiopathology , Female , Heart Function Tests , Humans , Isoenzymes/therapeutic use , Kidney Function Tests , Male , Pain Measurement , Quality of Life , Recombinant Proteins , Registries , Surveys and Questionnaires , Treatment OutcomeABSTRACT
The original guidelines drawn up for the management of the neuronopathic forms of Gaucher disease were felt to be in need of revision; in particular, the role of high-dose enzyme replacement therapy (120 IU/kg of body weight every 2 weeks) in stabilizing neurological disease. The existing published evidence was analysed; it was concluded that it did not support the role of high-dose ERT, although this might be required to treat severe visceral disease.
Subject(s)
Gaucher Disease/therapy , Health Planning Guidelines , Counseling , Enzyme Replacement Therapy/methods , Gaucher Disease/classification , Gaucher Disease/diagnosis , Humans , Social SupportABSTRACT
Fabry disease is a complex, multisystemic and clinically heterogeneous disease with prominent urinary excretion of globotriaosylceramide (Gb(3)), the principal substrate of the deficient enzyme, alpha-galactosidase A. Some measure of specific treatment is possible with enzyme replacement therapy, which can be applied safely and effectively to Fabry patients. Incidence estimations of Fabry disease vary widely from 1:55 000 to 1:3000 male births. The true incidence is likely to be higher than originally thought, owing to the existence of milder variants of the disease. The main complications of Fabry disease are a 100-fold increased risk of ischaemic stroke, cardiac disease, a wide variety of arrhythmias, valvular dysfunction and cardiac vascular disease, as well as progressive renal failure usually associated with significant proteinuria. These clinical manifestations are non-specific and are often mistaken for symptoms of other disorders, thus complicating the confirmation of diagnosis. Other clinical features of the disease are often absent (angiokeratoma), subtle (corneal opacities and hypohidrosis), or unaccompanied by specific physical findings (acroparaesthesias) indicating the true nature of the underlying disease. We propose the hypothesis that alpha-galactosidase A deficiency is a modifiable cardiovascular risk factor in the general population. This hypothesis may be tested by a non-invasive high-risk screening protocol for Fabry patients with ischaemic strokes and a variety of cardiac, and renal complications. These patients would benefit from diagnosis, appropriate treatment, follow-up and surveillance. Early detection of Fabry patients would also benefit affected relatives, many of whom do not have a clear diagnosis of their clinical condition.
Subject(s)
Fabry Disease/diagnosis , Kidney Diseases/diagnosis , Vascular Diseases/diagnosis , Algorithms , Brain Ischemia/diagnosis , Brain Ischemia/etiology , Chromatography, High Pressure Liquid , Fabry Disease/complications , Fabry Disease/urine , Humans , Kidney Diseases/complications , Mass Spectrometry , Risk Factors , Specimen Handling , Stroke/diagnosis , Stroke/etiology , Trihexosylceramides/urine , Vascular Diseases/complications , alpha-Galactosidase/geneticsABSTRACT
In order to identify new metabolic abnormalities in patients with complex neurodegenerative disorders of unknown aetiology, we performed high resolution in vitro proton nuclear magnetic resonance spectroscopy on patient cerebrospinal fluid (CSF) samples. We identified five adult patients, including two sisters, with significantly elevated free sialic acid in the CSF compared to both the cohort of patients with diseases of unknown aetiology (n = 144; P < 0.001) and a control group of patients with well-defined diseases (n = 91; P < 0.001). All five patients displayed cerebellar ataxia, with peripheral neuropathy and cognitive decline or noteworthy behavioural changes. Cerebral MRI showed mild to moderate cerebellar atrophy (5/5) as well as white matter abnormalities in the cerebellum including the peridentate region (4/5), and at the periventricular level (3/5). Two-dimensional gel analyses revealed significant hyposialylation of transferrin in CSF of all patients compared to age-matched controls (P < 0.001)--a finding not present in the CSF of patients with Salla disease, the most common free sialic acid storage disorder. Free sialic acid content was normal in patients' urine and cultured fibroblasts as were plasma glycosylation patterns of transferrin. Analysis of the ganglioside profile in peripheral nerve biopsies of two out of five patients was also normal. Sequencing of four candidate genes in the free sialic acid biosynthetic pathway did not reveal any mutation. We therefore identified a new free sialic acid syndrome in which cerebellar ataxia is the leading symptom. The term CAFSA is suggested (cerebellar ataxia with free sialic acid).
Subject(s)
Cerebellar Ataxia/cerebrospinal fluid , N-Acetylneuraminic Acid/cerebrospinal fluid , Adolescent , Adult , Aged , Aged, 80 and over , Atrophy/cerebrospinal fluid , Cells, Cultured , Cerebellar Ataxia/pathology , Cerebellum/pathology , Child , Child, Preschool , Cohort Studies , Female , Humans , Infant , Magnetic Resonance Imaging/methods , Magnetic Resonance Spectroscopy/methods , Male , Middle Aged , Transferrin/cerebrospinal fluidABSTRACT
OBJECTIVE: This is a study estimating diagnostic accuracy of CSF asialotransferrin to transferrin ratio measurement in eIF2B related disorders by using clinical evaluation and EIF2B mutation analysis as the reference standard. eIF2B-related disorder is a relatively common leukodystrophy with broad phenotypic variation that is caused by mutations in any of the five EIF2B genes. There is a need for a simple and clinically valid screening tool for physicians evaluating patients with an unclassified leukodystrophy. METHODS: CSF two-dimensional gel (2DG) electrophoresis analyses to measure asialotransferrin to transferrin ratios were performed in 60 subjects including 6 patients with documented EIF2B gene mutations, patients with other types of leukodystrophy, and patients with no leukodystrophy. RESULTS: All six patients with mutation proven eIF2B-related disease showed low to nearly undetectable amounts of asialotransferrin in their CSF when compared to 54 unaffected controls by CSF 2DG analyses in this study. eIF2B-like patients, with clinically similar presentations but no mutations in EIF2B1-5, were distinguished from patients with mutations in EIF2B1-5 by this biomarker. Patients with mutations in EIF2B1-5 had asialotransferrin/transferrin ratio levels significantly different from the group as a whole (p < 0.001). Using 8% asialotransferrin/transferrin ratio as a cutoff, this biomarker has a 100% sensitivity (95% CI = 52-100%) and 94% specificity (95% CI = 84-99%). CONCLUSION: Decreased asialotransferrin/transferrin ratio in the CSF of patients with eIF2B-related disorder is highly sensitive and specific. This rapid (<48 hours) and inexpensive diagnostic tool for eIF2B-related disorders has the potential to identify patients with likely eIF2B-related disorder for mutation analysis.
Subject(s)
Asialoglycoproteins/cerebrospinal fluid , Asialoglycoproteins/genetics , Eukaryotic Initiation Factor-2B/genetics , Transferrin/analogs & derivatives , Adult , Biomarkers/cerebrospinal fluid , Child , Child, Preschool , Dementia, Vascular/cerebrospinal fluid , Dementia, Vascular/diagnosis , Dementia, Vascular/genetics , Humans , Infant , Leukodystrophy, Globoid Cell/cerebrospinal fluid , Leukodystrophy, Globoid Cell/diagnosis , Leukodystrophy, Globoid Cell/genetics , Mutation , Sensitivity and Specificity , Transferrin/cerebrospinal fluid , Transferrin/geneticsSubject(s)
Charcot-Marie-Tooth Disease/genetics , Chromosomes, Human, Pair 1/genetics , Gaucher Disease/genetics , Genetic Predisposition to Disease/genetics , Uniparental Disomy/genetics , Charcot-Marie-Tooth Disease/complications , Child, Preschool , Chromosome Mapping , DNA Mutational Analysis , Gaucher Disease/complications , Genetic Markers/genetics , Glucosylceramidase/deficiency , Glucosylceramidase/genetics , Hearing Loss, Sensorineural/genetics , Hepatomegaly/genetics , Homozygote , Humans , Inheritance Patterns/genetics , Male , Microsatellite Repeats/genetics , Mutation , Myelin P0 Protein/genetics , Pupil Disorders/geneticsABSTRACT
BACKGROUND AND OBJECTIVE: Hypomyelination with atrophy of the basal ganglia and cerebellum is a recently defined disorder. Only a few patients have been described. We report on 11 additional patients and new MRI findings and provide histopathologic confirmation of the MRI interpretation. METHODS: We reviewed the patients' clinical history and present findings. We scored the MRI abnormalities. The histopathology of one patient was re-examined. RESULTS: The patients' early psychomotor development was normal or delayed, followed by increasing extrapyramidal movement abnormalities, ataxia, and spasticity. Mental capacities were variably affected. MRI showed hypomyelination with, on follow-up, evidence of further myelin loss and variable white matter atrophy. The putamen was small or, more often, absent; the head of the caudate nucleus was decreased in size. In contrast, the thalamus and globus pallidus remained normal. Cerebellar atrophy was invariably present. Histopathology confirmed the myelin deficiency, probably related to both lack of deposition and low-grade further loss. The degeneration of putamen was subtotal. The cerebellar cortex was affected, particularly the granular layer. CONCLUSION: Hypomyelination with atrophy of the basal ganglia and cerebellum is a syndrome diagnosed by distinctive MRI findings. Histopathology confirms hypomyelination, low-grade further myelin loss, subtotal degeneration of the putamen, and cerebellar cortical atrophy. All known patients are sporadic, and the mode of inheritance is unclear.
Subject(s)
Atrophy/pathology , Basal Ganglia/pathology , Cerebellum/pathology , Hereditary Central Nervous System Demyelinating Diseases/pathology , Heredodegenerative Disorders, Nervous System/pathology , Atrophy/genetics , Atrophy/physiopathology , Basal Ganglia/physiopathology , Basal Ganglia Diseases/genetics , Basal Ganglia Diseases/pathology , Basal Ganglia Diseases/physiopathology , Cerebellar Diseases/genetics , Cerebellar Diseases/pathology , Cerebellar Diseases/physiopathology , Cerebellum/physiopathology , Child , Child, Preschool , Disease Progression , Female , Hereditary Central Nervous System Demyelinating Diseases/genetics , Hereditary Central Nervous System Demyelinating Diseases/physiopathology , Heredodegenerative Disorders, Nervous System/genetics , Heredodegenerative Disorders, Nervous System/physiopathology , Humans , Inheritance Patterns/genetics , Magnetic Resonance Imaging , Male , Nerve Fibers, Myelinated/pathology , Predictive Value of Tests , SyndromeABSTRACT
Patients with the rare genetic disorders, xeroderma pigmentosum (XP), trichothiodystrophy (TTD) and Cockayne syndrome (CS) have defects in DNA nucleotide excision repair (NER). The NER pathway involves at least 28 genes. Three NER genes are also part of the basal transcription factor, TFIIH. Mutations in 11 NER genes have been associated with clinical diseases with at least eight overlapping phenotypes. The clinical features of these patients have some similarities but also have marked differences. NER is involved in protection against sunlight-induced DNA damage. While XP patients have 1000-fold increase in susceptibility to skin cancer, TTD and CS patients have normal skin cancer risk. Several of the genes involved in NER also affect somatic growth and development. Some patients have short stature and immature sexual development. TTD patients have sulfur deficient brittle hair. Progressive sensorineural deafness is an early feature of XP and CS. Many of these clinical diseases are associated with developmental delay and progressive neurological degeneration. The main neuropathology of XP is a primary neuronal degeneration. In contrast, CS and TTD patients have reduced myelination of the brain. These complex neurological abnormalities are not related to sunlight exposure but may be caused by developmental defects as well as faulty repair of DNA damage to neuronal cells induced by oxidative metabolism or other endogenous processes.
Subject(s)
Cockayne Syndrome/genetics , DNA Damage/genetics , DNA Repair/genetics , Mutation/genetics , Xeroderma Pigmentosum/genetics , Brain Diseases, Metabolic, Inborn/genetics , Brain Diseases, Metabolic, Inborn/metabolism , Brain Diseases, Metabolic, Inborn/physiopathology , Cockayne Syndrome/metabolism , Cockayne Syndrome/physiopathology , Heredodegenerative Disorders, Nervous System/genetics , Heredodegenerative Disorders, Nervous System/metabolism , Heredodegenerative Disorders, Nervous System/physiopathology , Humans , Phenotype , Skin Diseases, Genetic/genetics , Skin Diseases, Genetic/metabolism , Skin Diseases, Genetic/physiopathology , Xeroderma Pigmentosum/metabolism , Xeroderma Pigmentosum/physiopathologySubject(s)
Central Nervous System Cysts/diagnosis , Central Nervous System Cysts/genetics , Chromosome Aberrations , Eukaryotic Initiation Factor-2B/genetics , Genes, Recessive/genetics , Hereditary Central Nervous System Demyelinating Diseases/diagnosis , Hereditary Central Nervous System Demyelinating Diseases/genetics , Magnetic Resonance Imaging , Nerve Fibers, Myelinated/pathology , Brain/pathology , Diagnosis, Differential , Genetic Carrier Screening , HumansABSTRACT
Fabry disease, OMIM 301500, is a progressive multisystem storage disorder due to the deficiency of alpha-galactosidase A (GALA). Neurological and vascular manifestations of this disorder with regard to hearing loss have not been analysed quantitatively in large cohorts. We conducted a retrospective cross sectional analysis of hearing loss in 109 male and female patients with Fabry disease who were referred to and seen at the Clinical Center of the National Institutes of Health, Bethesda, MD, USA on natural history and enzyme replacement study protocols. There were 85 males aged 6-58 years (mean 31 years, SD 13) and 24 females aged 22-72 years (mean 42 years, SD 12). All patients underwent a comprehensive audiological evaluation. In addition, cerebral white matter lesions, peripheral neuropathy, and kidney function were quantitatively assessed. HL(95), defined as a hearing threshold above the 95th percentile for age and gender matched normal controls, was present in 56% [95% CI (42.2-67.2)] of the males. Prevalence of HL(95) was lower in the group of patients with residual GALA enzyme activity compared with those without detectable activity (33% versus 63%) HL(95) was present in the low-, mid- and high-frequency ranges for all ages. Male patients with HL(95) had a higher microvascular cerebral white matter lesion load [1.4, interquartile range (IQR) 0-30.1 +/- versus 0, IQR 0-0], more pronounced cold perception deficit [19.4 +/- 5.5 versus 13.5 +/- 5.5 of just noticeable difference (JND) units] and lower kidney function [creatinine: 1.6 +/- 1.2 versus 0.77 +/- 0.2 mg/dl; blood urea nitrogen (BUN): 20.1 +/- 14.1 versus 10.3 +/- 3.28 mg/dl] than those without HL(95) (P < 0.001). Of the females, 38% had HL(95). There was no significant association with cold perception deficit, creatinine or BUN in the females. Word recognition and acoustic reflexes analyses suggested a predominant cochlear involvement. We conclude that hearing loss involving all frequency regions significantly contributes to morbidity in patients with Fabry disease. Our quantitative analysis suggests a correlation of neuropathic and vascular damage with hearing loss in the males. Residual GALA activity appears to have a protective effect against hearing loss.
Subject(s)
Fabry Disease/physiopathology , Hearing Loss/physiopathology , Adolescent , Adult , Aged , Child , Cross-Sectional Studies , Ear, Middle/physiopathology , Fabry Disease/complications , Female , Hearing Loss/complications , Humans , Language , Male , Microcirculation , Middle Aged , Peripheral Nervous System Diseases/complications , Peripheral Nervous System Diseases/physiopathology , Psychological Tests , Retrospective Studies , Sensory Thresholds , Severity of Illness Index , Sex Factors , Telencephalon/blood supply , Tinnitus/complications , Tinnitus/physiopathology , alpha-Galactosidase/metabolismABSTRACT
Fabry disease results in a global vasculopathy leading to early-onset stroke and renal and cardiac failure. We found that random myeloperoxidase in serum and plasma was significantly elevated in 73 consecutive male patients with Fabry disease. Random serum myeloperoxidase level in men predicted the risk of a Fabry vasculopathy-related event in subsequent years. Long-term enzyme replacement therapy did not reduce myeloperoxidase level or eliminate the risk of vasculopathic events.
Subject(s)
Cardiovascular Diseases/enzymology , Fabry Disease/enzymology , Fabry Disease/genetics , Peroxidase/blood , Adolescent , Adult , Aged , Aged, 80 and over , Cardiovascular Diseases/etiology , Cardiovascular Diseases/genetics , Child , Fabry Disease/complications , Female , Follow-Up Studies , Humans , Male , Middle Aged , Peroxidase/genetics , Predictive Value of Tests , Prospective Studies , Risk FactorsABSTRACT
We identified four unrelated patients (three female, one male) aged 20 to 30 years with hypomyelination, pituitary hypogonadotropic hypogonadism, and hypodontia. Electron microscopy and myelin protein immunohistochemistry of sural nerves showed granular debris-lined clefts, expanded abaxonal space, outpocketing with vacuolar disruption, and loss of normal myelin periodicity. Reduced galactocerebroside, sphingomyelin, and GM1-N-acetylglucosamine and increased esterified cholesterol were found. This is a clinically homogeneous progressive hypomyelinating disorder. The term 4H syndrome is suggested.
Subject(s)
Anodontia/pathology , Demyelinating Diseases/pathology , Hypogonadism/pathology , Adult , Anodontia/complications , Demyelinating Diseases/complications , Female , Humans , Hypogonadism/complications , Male , Pituitary Gland/pathology , Sural Nerve/pathologySubject(s)
Gaucher Disease/diagnosis , Skin Abnormalities/pathology , Diagnosis, Differential , Epidermis/metabolism , Epidermis/pathology , Gaucher Disease/classification , Gaucher Disease/genetics , Glucosylceramidase/analysis , Glucosylceramidase/deficiency , Humans , Ichthyosis/diagnosis , Ichthyosis/genetics , Male , PrognosisABSTRACT
BACKGROUND: Alexander disease is most commonly associated with macrocephaly and, on MRI, a leukoencephalopathy with frontal preponderance. The disease is caused by mutation of the GFAP gene. Clinical and MRI phenotypic variation have been increasingly recognized. METHODS: The authors studied seven patients with Alexander disease, diagnosed based on mutations in the GFAP gene, who presented unusual MRI findings. The authors reviewed clinical history, MRI abnormalities, and GFAP mutations. RESULTS: All patients had juvenile disease onset with signs of brainstem or spinal cord dysfunction. None of the patients had a macrocephaly. The MRI abnormalities were dominated by medulla and spinal cord abnormalities, either signal abnormalities or atrophy. One patient had only minor cerebral white matter abnormalities. A peculiar finding was the presence of a kind of garland along the ventricular wall in four patients. Three patients had an unusual GFAP mutation, one of which was a duplication mutation of two amino acids, and one an insertion deletion. CONCLUSION: Signal abnormalities or atrophy of the medulla or spinal cord on MRI are sufficient to warrant DNA analysis for Alexander disease. Ventricular garlands constitute a new sign of the disease. Unusual phenotypes of Alexander disease are found among patients with late onset and protracted disease course.
Subject(s)
Alexander Disease/pathology , Brain/abnormalities , Cerebral Ventricles/pathology , Glial Fibrillary Acidic Protein/genetics , Medulla Oblongata/abnormalities , Spinal Cord/abnormalities , Adolescent , Adult , Alexander Disease/genetics , Female , Humans , Magnetic Resonance Imaging , Medulla Oblongata/pathology , Mutation , Spinal Cord/pathologyABSTRACT
The inherited disorders of CNS myelin formation represent a heterogeneous group of leukodystrophies. The proteolipoprotein (PLP1) gene has been implicated in two X-linked forms, Pelizaeus-Merzbacher disease (PMD) and spastic paraplegia type 2, and the gap junction protein alpha12 (GJA12) gene in a recessive form of PMD. The myelin basic protein (MBP) gene, which encodes the second most abundant CNS myelin protein after PLP1, presents rearrangements in hypomyelinating murine mutants and is always included in the minimal region deleted in 18q- patients with an abnormal hypomyelination pattern on cerebral MRI. In this study, we looked at the genomic copy number at the Golli-MBP locus in 195 patients with cerebral MRI suggesting a myelin defect, who do not have PLP1 mutation. Although preliminary results obtained by FISH suggested the duplication of Golli-MBP in 3 out of 10 patients, no abnormal gene quantification was found using Quantitative Multiplex PCR of Short Fluorescent fragments (QMPSF), Multiplex Amplifiable Probe Hybridization (MAPH), or another FISH protocol using directly-labelled probes. Pitfalls and interest in these different techniques to detect duplication events are emphasised. Finally, the study of this large cohort of patients suggests that Golli-MBP deletion or duplication is rarely involved in inherited defects of myelin formation.
Subject(s)
Gene Dosage/genetics , Nerve Tissue Proteins/genetics , Paraplegia/genetics , Pelizaeus-Merzbacher Disease/genetics , Transcription Factors/genetics , DNA Primers , DNA Probes/genetics , Gene Duplication , Humans , In Situ Hybridization, Fluorescence , Magnetic Resonance Imaging , Membrane Proteins , Myelin Basic Protein , Myelin Proteolipid Protein , Polymerase Chain Reaction/methodsABSTRACT
BACKGROUND: Gaucher disease is classified into neuronopathic and non-neuronopathic forms with wide phenotypic variation among patients sharing the same genotype. While homozygosity for the common L444P allele usually correlates with the neuronopathic forms, how a defined genotype leads to a phenotype remains unknown. METHODS: The genetic and epigenetic factors causing phenotypic differences were approached by a clinical association study in 32 children homozygous for the point mutation L444P. Direct sequencing and Southern blots were utilised to establish the genotype and exclude recombinant alleles. Glucocerebrosidase activity was measured in lymphoblast and fibroblast cell lines. RESULTS: Residual enzyme activity was highly variable and did not correlate with the observed clinical course. There was also a wide spectrum of phenotypes. Average age at diagnosis was 15 months, and slowed saccadic eye movements were the most prevalent finding. The most severe systemic complications and highest mortality occurred in splenectomised patients before the advent of enzyme replacement therapy (ERT). On ERT, as morbidity and mortality decreased, developmental and language deficits emerged as a major issue. Some trends related to ethnic background were observed. CONCLUSION: The wide clinical spectrum observed in the L444P homozygotes implicates the contribution of genetic modifiers in defining the phenotype in Gaucher disease.